Source:http://linkedlifedata.com/resource/pubmed/id/15083753
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2004-4-15
|
| pubmed:abstractText |
The aim of this study was to examine the dose-response relationship of inhaled budesonide in adolescents and adults with asthma. A meta-analysis was carried out on placebo-controlled, randomised clinical trials, presenting data on at least one outcome measure of asthma and using at least two doses of budesonide, delivered by turbuhaler or metered-dose inhaler + spacer twice daily. A total of six studies of 1,435 adolescents and adults, with mild to moderately severe asthma, met the inclusion criteria for the meta-analysis. A negative exponential model indicated that 80% of the benefit at 1,600 micrograms.day-1 was achieved at doses of approximately 200-400 micrograms.day-1 and 90% by 300-600 micrograms.day-1. Meta-regression with a quadratic term in dose showed that the maximum effect was obtained with doses of approximately 1,000 micrograms.day-1. In conclusion, the available published data indicate that, in adolescents and adults with mild to moderate asthma, most of the therapeutic benefit of budesonide delivered by turbuhaler or metered-dose inhaler + spacer is achieved with a dose of approximately 400 micrograms.day-1 and the maximum effect is achieved at approximately 1,000 micrograms.day-1. This conclusion is qualified by the recognition that there is considerable individual variability in the response to inhaled corticosteroids and that the subjects included in this meta-analysis had predominantly mild to moderate asthma.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0903-1936
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
23
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
552-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15083753-Administration, Inhalation,
pubmed-meshheading:15083753-Adolescent,
pubmed-meshheading:15083753-Adult,
pubmed-meshheading:15083753-Anti-Inflammatory Agents,
pubmed-meshheading:15083753-Asthma,
pubmed-meshheading:15083753-Bronchodilator Agents,
pubmed-meshheading:15083753-Budesonide,
pubmed-meshheading:15083753-Dose-Response Relationship, Drug,
pubmed-meshheading:15083753-Forced Expiratory Volume,
pubmed-meshheading:15083753-Humans,
pubmed-meshheading:15083753-Nebulizers and Vaporizers,
pubmed-meshheading:15083753-Peak Expiratory Flow Rate,
pubmed-meshheading:15083753-Placebos,
pubmed-meshheading:15083753-Randomized Controlled Trials as Topic,
pubmed-meshheading:15083753-Regression Analysis,
pubmed-meshheading:15083753-Remission Induction,
pubmed-meshheading:15083753-Treatment Outcome
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis.
|
| pubmed:affiliation |
Medical Research Institute of New Zealand, PO Box 10055, Wellington, New Zealand.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Meta-Analysis
|